Can plants reveal the secrets of survival during Earth's darkest days? At an outcrop north of Sydney, Australia, the research ...

Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy ...

Primary endpoint showed clinically meaningful improvement in patients with SMA receiving apitegromab as measured by gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo ...

Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA.

Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates. CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical ...

Primary endpoint showed clinically meaningful improvement in patients with SMA receiving apitegromab as measured by gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

Image credit: Ines Nepo / Shutterstock. Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal study, but investors are not ...

Broadway’s 2024-25 season has gotten off to a rather extraordinarily fine start, from the wildly popular and hysterically funny Oh, Mary! to the fabulous splash of Death Becomes Her and the wonderful ...

--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other ...

This month marks the fifth anniversary of the pandemic. We asked students how their lives are different today because of it. By The Learning Network President Trump abruptly stopped providing ...